A gene therapy approach is ideally suited for early onset DTDS, as there is a well-defined midbrain target for gene supplementation with the wildtype SLC6A3 gene to treat causative biallelic loss-of-function mutations. The gene discussed is SLC6A3; the disease is SLC6A3-related dopamine transporter deficiency syndrome.